pfizer novo nordisk - Search News

Novo Nordisk Launches Bidding War With Pfizer

Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for Metsera

Novo Nordisk on Thursday launched an unsolicited bid valued at up to $9 billion for obesity-drug developer Metsera, hoping to top the deal Pfizer reached last month and teeing up a potential legal battle for the biotech company.

· 12h · on MSN

Novo Nordisk launches bidding war with Pfizer for US obesity biotech Metsera

· 1h · on MSN

Explained: Inside Novo Nordisk’s $9 Billion bid to outmuscle Pfizer

· 14h

Metsera the US obesity biotech at centre of Novo, Pfizer bidding war

The bidding may signal a new phase in the obesity drug race, which was ignited in 2021 by Novo's launch of Wegovy, the first highly effective obesity drug approved in the U.S.

· 10h

Novo Crashes Pfizer's Party with Surprise $6.5B Power Move for Metsera

· 20h

Novo Nordisk makes unsolicited offer for Metsera

· 17h

Novo Nordisk's bid for Metsera, Eli Lilly boosts revenue outlook

Eli Lily beating estimates and boosting its full-year revenue guidance.

· 20h

Novo Nordisk gatecrashes Pfizer's takeover of obesity rival Metsera

· 17h

Novo Nodrisk stock dips on aggressive odder to buy Metsera, ’reckless’ says Pfizer

12hon MSN

Novo Nordisk Tries to Snatch a Weight-Loss Biotech From Pfizer. There Are Political Risks.

Denmark’s Novo offers $56.50 a share in cash for Metsera, plus potentially a further $21.25 a share based on clinical and regulatory milestones.

Fierce Biotech

Novo makes bombshell $6.5B counteroffer to Pfizer's acquisition of obesity biotech Metsera

For Novo, it marks the boldest move yet for recently appointed CEO Maziar Mike Doustdar. In response to a slowdown in sales growth for its blockbuster obesity drug Wegovy, Doustdar has already announced plans to lay off about 9,000 employees worldwide and shutter the company’s cell therapy R&D work.